Inovio tumbles on $75 mln stock sale for rare throat disease drug

** Shares of Inovio Pharmaceuticals INO.O tumble 20% to $1.16 in premarket trading on Fri after $75 mln follow-on priced

** INO late Thurs sold ~71.4 mln shares, including pre-funded warrants, at $1.05

** Offering priced at 27.6% discount to stock's last sale of $1.45

** On Mon, INO shares more than tripled to finish at $1.89 after the US FDA approved co's rare throat disease treatment, branded as Voceryq

** INO intends to use net offering proceeds to fund commercial launch of Voceryq, for development of its clinical pipeline among other purposes, per the prospectus

** Jefferies and Piper Sandler joint bookrunners

** Plymouth Meeting, Pennsylvania-based INO has ~110.2 mln shares outstanding as of Sept 30

** All three analysts covering the stock are bullish and their PTs are $3, $5 and $8, per LSEG data